180
Participants
Start Date
July 5, 2022
Primary Completion Date
July 31, 2028
Study Completion Date
August 31, 2028
Odevixibat
Odevixibat is a small molecule inhibitor of the ileal bile acid transporter (IBAT).
Starship Child Health, Te Whatu Ora - Health New Zealand, Auckland
Royal Children's Hospital, Parkville
Hassenfeld Children's Hospital at NYU Langone, New York
Columbia University Medical Center New York Presbyterian Morgan Stanley-Komansky Childrens Hospital, New York
The Childrens Hospital at Montefiore Albert Einstein School of Medicine, The Bronx
Children's Healhcare of Atlanta- Emory University school of medicine, Atlanta
Cincinnati Children's Hospital Medical Center, Cincinnati
Indiana University school of Medicine, Indianapolis
University Malaya Medical Centre, Kuala Lumpur
Children's Mercy Hospital and Clinics, Kansas City
Children's Hospital Colorado, Aurora
Seattle Children's Hospital, Seattle
Boston Children's Hospital, Boston
CHU Sainte-Justine, Montreal
The Hospital for Sick Children, Toronto
Guangzhou Women And Childrens Medical Center, Guangdong
Children's Hospital of Fudan University, Shanghai
Bicêtre Hospital, Le Kremlin-Bicêtre
Charité - Universitätsmedizin Berlin, Berlin
University Children´s Hospital Tuebingen, Tübingen
ASST Papa Giovanni XXIII, Bergamo
Azienda Ospedaliera di Padova, Padua
Hospital Raja Perempuan Zainab II, Kota Bharu
University Medical Center Groningen, Groningen
Instytut Pomnik-Centrum Zdrowia Dziecka, Warsaw
Seoul National University Childrens Hospital, Seoul
Hospital Universitari Vall d'Hebron, Barcelona
Hacettepe İhsan Doğramacı Children's Hospital, Ankara
Akdeniz University Medical Faculty, Antalya
Istanbul University Istanbul Medical Faculty Hospital, Istanbul
Albireo, an Ipsen Company
INDUSTRY